These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31757842)

  • 1. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
    Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
    J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim FDG
    Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
    Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
    Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
    Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?
    Le Gouill S; Casasnovas RO
    Blood; 2017 Jun; 129(23):3059-3070. PubMed ID: 28416502
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
    Schöder H; Polley MC; Knopp MV; Hall N; Kostakoglu L; Zhang J; Higley HR; Kelloff G; Liu H; Zelenetz AD; Cheson BD; Wagner-Johnston N; Kahl BS; Friedberg JW; Hsi ED; Leonard JP; Schwartz LH; Wilson WH; Bartlett NL
    Blood; 2020 Jun; 135(25):2224-2234. PubMed ID: 32232481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
    de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
    Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
    Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
    J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
    Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
    Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.
    Torka P; Pederson LD; Knopp MV; Poon D; Zhang J; Kahl BS; Higley HR; Kelloff G; Friedberg JW; Schwartz LH; Wilson WH; Leonard JP; Bartlett NL; Schöder H; Ruppert AS
    Cancer Med; 2023 Apr; 12(7):8211-8217. PubMed ID: 36799072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.
    Zaman MU; Fatima N; Zaman A; Zaman U; Zaman S; Tahseen R
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2343-2348. PubMed ID: 32856864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.